Clinical data | |
---|---|
Trade names | Mevacor, Altocor, others |
Other names | Monacolin K, Mevinolin |
AHFS/Drugs.com | Monograph |
MedlinePlus | a688006 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | <5%[1] |
Protein binding | >98%[1] |
Metabolism | Liver (CYP3A and CYP2C8 substrate)[1] |
Elimination half-life | 2–5 hours[1] |
Excretion | Faeces (83%), urine (10%)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.115.931 |
Chemical and physical data | |
Formula | C24H36O5 |
Molar mass | 404.547 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Lovastatin, sold under the brand name Mevacor among others, is a statin medication, to treat high blood cholesterol and reduce the risk of cardiovascular disease.[2] Its use is recommended together with lifestyle changes.[2] It is taken by mouth.[2]
Common side effects include diarrhea, constipation, headache, muscles pains, rash, and trouble sleeping.[2] Serious side effects may include liver problems, muscle breakdown, and kidney failure.[2] Use during pregnancy may harm the baby and use during breastfeeding is not recommended.[3] It works by decreasing the liver's ability to produce cholesterol by blocking the enzyme HMG-CoA reductase.[2]
Lovastatin was patented in 1979 and approved for medical use in 1987.[4] It is on the World Health Organization's List of Essential Medicines.[5] It is available as a generic medication.[2] In 2022, it was the 111th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[6][7]